Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.\n\nGNH India supplies Imatinib Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a targeted tyrosine‑kinase inhibitor used in hematologic and solid‑tumor oncology.\n\n- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and helps achieve cytogenetic and molecular remission.\n- Gastrointestinal stromal tumor (GIST): blocks KIT/PDGFRA‑driven tumor growth and improves progression‑free survival.\n- Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Adverse reactions may occur with imatinib therapy.\n\nCommon Side Effects:\n- Nausea\n- Edema\n- Muscle cramps\n- Fatigue\n\nSerious or Rare Side Effects:\n- Hepatotoxicity\n- Severe neutropenia\n- Cardiac failure

Patients receiving Imatinib should be monitored for safety and efficacy.\n\n- Monitor blood counts: regular CBC to detect cytopenias.\n- Assess liver function: periodic LFTs for hepatotoxicity.\n- Evaluate cardiac status: baseline ECG and watch for signs of heart failure.\n- Avoid use in individuals with known hypersensitivity to imatinib.\n- Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Imatinib may interact with several concomitant medicines.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib exposure.\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease efficacy.\n- Antacids containing aluminum or magnesium: reduce oral absorption if taken simultaneously.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may enhance anticoagulant effect; monitor INR.\n- Proton pump inhibitors: may modestly lower imatinib levels; observe therapeutic response.\n- Live attenuated vaccines: possible reduced efficacy; consider timing of vaccination.